Multiple copies of mutant BRCA1 and BRCA2 alleles in breast tumors from germ‐line mutation carriers

Inactivation of the BRCA1 and BRCA2 breast cancer susceptibility genes has been reported to occur via a germ‐line mutation of one allele and a somatic loss of the remaining wild‐type allele. We investigated the genetic mechanisms behind the second event in breast tumors from 17 BRCA1 and eight BRCA2 germ‐line mutation carriers, as compared with 21 sporadic breast tumors. Microsatellite markers intragenic or in close proximity to both genes were used to analyze imbalances between the mutant and wild‐type alleles. The actual and relative gene copy numbers were scored by fluorescence in situ hybridization (FISH) analysis of tumor cells using locus and centromere specific probes. All but one of the informative BRCA1 and BRCA2 tumors exhibited allelic imbalance and loss of the corresponding wild type allele. In contrast to sporadic tumors, however, where allelic imbalance at the BRCA1 and BRCA2 loci correlated well with relative copy number losses by FISH, a simple reduction to a single copy (average copy number ratio 2:1) was found in only two BRCA1 (12%) and four BRCA2 (50%) tumors. The majority of BRCA1 and BRCA2 tumors showed a copy number reduction (relative to reference probe with ratios 4:2, 3:2, 4:3) at corresponding loci, suggesting that a specific physical deletion of the wild‐type BRCA gene allele has been followed by a duplication of the remaining mutant allele via polyploidization. Several tumors contained multiple copies of BRCA1 and BRCA2 genes without relative copy number changes, implying that loss of wild‐type alleles is executed by alternative mechanisms such as mitotic recombination, non‐disjunctional chromosomal loss with or without reduplication, or by gene conversion. A paradoxical relative copy number gain of the mutant allele was evident in three BRCA1 tumors (18%), which could be of biological relevance if a dominant negative or gain‐of‐function model was ascribed for certain BRCA1 mutants. Our results indicate that complex genetic alterations are operational at the BRCA1 and BRCA2 loci in tumors from genetically predisposed individuals. Genes Chromosomes Cancer 28:432–442, 2000. © 2000 Wiley‐Liss, Inc.

[1]  A. Levine,et al.  Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy , 1999, Oncogene.

[2]  T. Ouchi,et al.  The BRCA2 gene product functionally interacts with p53 and RAD51. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[3]  A. Bowcock,et al.  The C-terminal (BRCT) Domains of BRCA1 Interact in Vivo with CtIP, a Protein Implicated in the CtBP Pathway of Transcriptional Repression* , 1998, The Journal of Biological Chemistry.

[4]  B. Koller,et al.  BRCA1 required for transcription-coupled repair of oxidative DNA damage. , 1998, Science.

[5]  M. Fernö,et al.  Genetic aberrations in hypodiploid breast cancer: frequent loss of chromosome 4 and amplification of cyclin D1 oncogene. , 1998, The American journal of pathology.

[6]  L. Norton,et al.  BRCA-associated breast cancer: absence of a characteristic immunophenotype. , 1998, Cancer research.

[7]  Hui Tian,et al.  BRCA1 physically associates with p53 and stimulates its transcriptional activity , 1998, Oncogene.

[8]  A. Børresen-Dale,et al.  Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters. , 1998, Cancer research.

[9]  J Isola,et al.  Molecular cytogenetics of primary breast cancer by CGH , 1998, Genes, chromosomes & cancer.

[10]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[11]  T. Ouchi,et al.  The BRCA 2 gene product functionally interacts with p 53 and RAD 51 , 1998 .

[12]  D. Birnbaum,et al.  Genome-wide search for loss of heterozygosity shows extensive genetic diversity of human breast carcinomas. , 1997, Cancer research.

[13]  A. Ashworth,et al.  Nuclear location and cell cycle regulation of the BRCA2 protein. , 1997, Cancer research.

[14]  B. Gusterson,et al.  p53 mutations in BRCA1-associated familial breast cancer , 1997, The Lancet.

[15]  M. King,et al.  Population genetics of BRCA1 and BRCA2. , 1997, American journal of human genetics.

[16]  Å. Borg,et al.  Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer. , 1997, American journal of human genetics.

[17]  G. Eichele,et al.  Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2 , 1997, Nature.

[18]  J Isola,et al.  Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. , 1997, Cancer research.

[19]  Å. Borg,et al.  Tumour biological features of BRCA1-induced breast and ovarian cancer. , 1997, European journal of cancer.

[20]  Yonghong Xiao,et al.  Association of BRCA1 with Rad51 in Mitotic and Meiotic Cells , 1997, Cell.

[21]  K. Kinzler,et al.  Cancer-susceptibility genes. Gatekeepers and caretakers. , 1997, Nature.

[22]  Anne M. Bowcock,et al.  Identification of a RING protein that can interact in vivo with the BRCA1 gene product , 1996, Nature Genetics.

[23]  H. Hanafusa,et al.  Evidence for a transcriptional activation function of BRCA1 C-terminal region. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Å. Borg,et al.  Allelic loss at chromosome 13q12-q13 is associated with poor prognosis in familial and sporadic breast cancer. , 1996, British Journal of Cancer.

[25]  H. Caffier,et al.  A somatic truncating mutation in BRCA2 in a sporadic breast tumor. , 1996, American journal of human genetics.

[26]  Sheila Seal,et al.  BRCA2 mutations in primary breast and ovarian cancers , 1996, Nature Genetics.

[27]  M. Skolnick,et al.  Low incidence of BRCA2 mutations in breast carcinoma and other cancers , 1996, Nature Genetics.

[28]  Yusuke Nakamura,et al.  Mutation analysis in the BRCA2 gene in primary breast cancers , 1996, Nature Genetics.

[29]  M. Beckmann,et al.  Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer. , 1996, British Journal of Cancer.

[30]  M. King,et al.  Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden. , 1996, American journal of human genetics.

[31]  J. Rommens,et al.  The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds , 1996, Nature Genetics.

[32]  D. Bentley,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.

[33]  J. Gudmundsson,et al.  Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12-q13. , 1995, Cancer research.

[34]  S. Hilsenbeck,et al.  Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. , 1995, The American journal of pathology.

[35]  D. Easton,et al.  Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. , 1995, Oncogene.

[36]  W. Kuo,et al.  A physical map of chromosome 20 established using fluorescence in situ hybridization and digital image analysis. , 1995, Genomics.

[37]  P. Devilee,et al.  Somatic genetic changes in human breast cancer. , 1994, Biochimica et biophysica acta.

[38]  S. Neuhausen,et al.  Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds. , 1994, Cancer Research.

[39]  M. Skolnick,et al.  BRCA1 mutations in primary breast and ovarian carcinomas. , 1994, Science.

[40]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[41]  S. Seal,et al.  Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. , 1994, Science.

[42]  E. Fujimoto,et al.  A physical map and candidate genes in the BRCA1 region on chromosome 17q12–21 , 1994, Nature Genetics.

[43]  Cécile Fizames,et al.  The 1993–94 Généthon human genetic linkage map , 1994, Nature Genetics.

[44]  Å. Borg,et al.  High frequency of allelic imbalance at the BRCA1 region on chromosome 17q in both familial and sporadic ductal breast carcinomas. , 1994, Journal of the National Cancer Institute.

[45]  W. Kuo,et al.  A candidate tumor suppressor gene in human breast cancers. , 1994, Cancer research.

[46]  C. Amemiya,et al.  A new bacteriophage P1–derived vector for the propagation of large human DNA fragments , 1994, Nature Genetics.

[47]  A. Levine.  The tumor suppressor genes. , 1993, Annual review of biochemistry.

[48]  D. Easton,et al.  Allele losses in the region 17q12–21 in familial breast and ovarian cancer involve the wild–type chromosome , 1992, Nature Genetics.

[49]  C. Marshall.  Tumor suppressor genes , 1991, Cell.

[50]  M. King,et al.  Linkage of early-onset familial breast cancer to chromosome 17q21. , 1990, Science.

[51]  M. Meuth.  The structure of mutation in mammalian cells. , 1990, Biochimica et biophysica acta.

[52]  W. J. Brammar,et al.  The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumours. , 1989, Oncogene.

[53]  J. Varley,et al.  Structural rearrangement of the retinoblastoma gene in human breast carcinoma. , 1988, Science.